Monte Rosa Therapeutics (GLUE) said Monday that the first patients have been dosed in its phase 1 study of MRT-8102 for the treatment of multiple inflammatory diseases.
The study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of the drug in healthy volunteers, the company said.
Monte Rosa said it expects the initial results of the study in H1 of 2026.
The company's shares were up 6.2% in premarket activity on Monday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。